RepliCel Life Sciences Balance Sheet Health
Financial Health criteria checks 0/6
RepliCel Life Sciences has a total shareholder equity of CA$-6.6M and total debt of CA$811.4K, which brings its debt-to-equity ratio to -12.2%. Its total assets and total liabilities are CA$331.5K and CA$7.0M respectively.
Key information
-12.2%
Debt to equity ratio
CA$811.39k
Debt
| Interest coverage ratio | n/a |
| Cash | CA$32.48k |
| Equity | -CA$6.64m |
| Total liabilities | CA$6.97m |
| Total assets | CA$331.47k |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: REPC.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: REPC.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: REPC.F has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: REPC.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: REPC.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: REPC.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.2% each year.